Paletta Guedes Eye Institute.
Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
J Glaucoma. 2019 Apr;28(4):363-366. doi: 10.1097/IJG.0000000000001191.
To assess the efficacy and safety of the Ologen collagen matrix as an adjuvant for combined phacoemulsification and nonpenetrating deep sclerectomy (Phaco-NPDS), in addition to mitomycin C (MMC).
This was a longitudinal retrospective comparative study of eyes treated with Phaco-NPDS, with (group 1) or without (group 2) an Ologen collagen matrix implant, in addition to MMC. The main outcome measures were operative success [absolute success: intraocular pressure (IOP) <18 mm Hg and an at least 20% reduction from baseline without medication; relative success: IOP<18 mm Hg and at least 20% reduction from baseline IOP with or without medication], mean reductions (%) in IOP and medication use; number of postoperative reinterventions (goniopuncture, needling, reoperation), and number of complications.
The mean age of the study population (N=100) was 72.0±9.7 years. Groups 1 (n=51) and 2 (n=49) achieved absolute success rates of 72.5% and 55.1%, respectively (P=0.054), and relative success rates of 90.2% and 83.7%, respectively (P=0.251). From a similar baseline IOP (19.8 and 20.7 mm Hg in groups 1 and 2, respectively, P=0.527), eyes in group 1 achieved a significant lower 12-month IOP (11.7 vs. 14.5 mm Hg, respectively, P=0.002) and a lower rate of medication use (0.2 vs. 0.9, respectively, P<0.001). Eyes in group 2 presented with a higher rate of bleb failure (12.2% vs. 2.0%, P=0.028), leading to a higher rate of needling procedures (38.8% vs. 2.0%, P<0.001) during the postoperative period.
The adjunctive use of Ologen collagen matrix in addition to MMC during Phaco-NPDS was associated with a higher rate of absolute success, a lower mean IOP at 12 months, a lower rate of bleb failure, and a lower rate of postoperative bleb needling.
评估 Ologen 胶原基质作为辅助物联合超声乳化白内障吸除术和非穿透性深层巩膜切除术（Phaco-NPDS）联合丝裂霉素 C（MMC）的疗效和安全性。
这是一项对接受 Phaco-NPDS 治疗的眼进行的纵向回顾性比较研究，其中（第 1 组）或未（第 2 组）使用 Ologen 胶原基质植入物联合 MMC。主要观察指标为手术成功率[绝对成功率：眼压（IOP）<18mmHg 且较基线下降至少 20%，无需药物治疗；相对成功率：IOP<18mmHg 且较基线 IOP 下降至少 20%，无论是否需要药物治疗]、IOP 和药物使用的平均降低率（%）；术后再介入（房角穿刺术、针刺术、再次手术）的次数和并发症的数量。
研究人群（N=100）的平均年龄为 72.0±9.7 岁。第 1 组（n=51）和第 2 组（n=49）的绝对成功率分别为 72.5%和 55.1%（P=0.054），相对成功率分别为 90.2%和 83.7%（P=0.251）。从相似的基线 IOP（第 1 组和第 2 组分别为 19.8 和 20.7mmHg，P=0.527）开始，第 1 组的 12 个月 IOP 显著降低（分别为 11.7 和 14.5mmHg，P=0.002），药物使用率降低（分别为 0.2 和 0.9，P<0.001）。第 2 组的滤过泡失败率较高（12.2%与 2.0%，P=0.028），导致术后针刺术的发生率较高（38.8%与 2.0%，P<0.001）。
在 Phaco-NPDS 中联合使用 Ologen 胶原基质和 MMC 可提高绝对成功率，降低 12 个月时的平均眼压，降低滤过泡失败率，并降低术后滤过泡针刺术的发生率。
